ViewRay, Inc. (NASDAQ:VRAY) tinted gains of +4.23% (+0.36 points) to US$8.88. The volume of 0.76 Million shares climbed down over an trading activity of 721.24 Million shares. EPS ratio determined by looking at last 12 month figures is -0.82. Over the same time span, the stock marked US$10.64 as its best level and the lowest price reached was US$4.4. The corporation has a market cap of US$647.8 Million.
ViewRay, Inc. (NASDAQ:VRAY)’s earnings per share has been growing at a -13.4 percent rate over the past 5 year when average revenue increase was noted as 79 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -103.6 percent. The company’s institutional ownership is monitored at 79.9 percent. The company’s net profit margin has achieved the current level of -87.7 percent and possesses 19.9 percent gross margin.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is worth US$904.43 Million and has recently risen 4.17% to US$7.5. The latest exchange of 2.9 Million shares is above its average trading activity of 2.08 Million shares. The day began at US$7.2 but the price moved to US$7.2 at one point during the trading and finally capitulating to a session high of US$7.5. The stock tapped a 52-week high of US$10.65 while the mean 12-month price target for the shares is US$21.42.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.72, and a price to sales ratio of 5.9. For the past 5 years, the company’s revenue has grown 204.1%, while the company’s earnings per share has grown 17.9%. With an institutional ownership near 20.9%, it carries an earnings per share ratio of -0.04.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.67.